{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:07:15Z","timestamp":1790255235266,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201262","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:11:38Z","timestamp":1781201498000},"page":"201262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Srinivas Vinod","family":"Saladi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen L.","family":"Weisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail E.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhika","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Podar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-4199","authenticated-orcid":false,"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201262_bib1","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2217\/fon-2021-1355","article-title":"Efficacy of non-intensive therapies approved for relapsed\/refractory acute myeloid leukemia: a systematic literature review","volume":"18","author":"Russell-Smith","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.omton.2026.201262_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201262_bib3","first-page":"59","article-title":"Venetoclax-Azacitidine, the new standard of care for AML patients unfit for intensive treatment: A guide for clinical practice","volume":"14","author":"Moors","year":"2023","journal-title":"Belg. J. Hematol."},{"key":"10.1016\/j.omton.2026.201262_bib4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/hematolrep15040063","article-title":"Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations","volume":"15","author":"Garg","year":"2023","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.omton.2026.201262_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105124","article-title":"CARM1 arginine methyltransferase as a therapeutic target for cancer","volume":"299","author":"Santos","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201262_bib6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ccell.2018.05.007","article-title":"CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis","volume":"33","author":"Greenblatt","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201262_bib7","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/2159-8290.CD-20-1144","article-title":"CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells","volume":"11","author":"Kumar","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201262_bib8","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1038\/s41467-024-47689-4","article-title":"Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity","volume":"15","author":"Itonaga","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201262_bib9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.celrep.2013.11.025","article-title":"PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex","volume":"5","author":"Vu","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201262_bib10","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.3390\/molecules25143122","article-title":"Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300\/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells","volume":"25","author":"Fioravanti","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.omton.2026.201262_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.7150\/ijbs.41230","article-title":"The CARM1-p300-c-Myc-Max (CPCM) transcriptional complex regulates the expression of CUL4A\/4B and affects the stability of CRL4 E3 ligases in colorectal cancer","volume":"16","author":"Lu","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omton.2026.201262_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201262_bib13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41594-022-00881-w","article-title":"Human DNA-dependent protein kinase activation mechanism","volume":"30","author":"Liang","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omton.2026.201262_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201262_bib15","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2008-07-172148","article-title":"BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair","volume":"114","author":"Fernandes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201262_bib16","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201262_bib17","doi-asserted-by":"crossref","first-page":"18480","DOI":"10.18632\/oncotarget.24883","article-title":"TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma","volume":"9","author":"Nakayama","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201262_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2013.12.007","article-title":"CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis","volume":"25","author":"Wang","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201262_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-023-10153-8","article-title":"From modulation of cellular plasticity to potentiation of therapeutic resistance: new and emerging roles of MYB transcription factors in human malignancies","volume":"43","author":"Anand","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.omton.2026.201262_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.trecan.2023.06.008","article-title":"Beyond gene expression: how MYC relieves transcription stress","volume":"9","author":"Papadopoulos","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2026.201262_bib21","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201262_bib22","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","article-title":"Internal tandem duplication of FLT3 (FLT3\/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML","volume":"111","author":"Sallmyr","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201262_bib23","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3390\/biom11101487","article-title":"DNA End Joining: G0-ing to the Core","volume":"11","author":"Frock","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.omton.2026.201262_bib24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41586-023-05780-8","article-title":"H3K4me3 regulates RNA polymerase II promoter-proximal pause-release","volume":"615","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201262_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tcb.2020.12.010","article-title":"CARM1\/PRMT4: Making Its Mark beyond Its Function as a Transcriptional Coactivator","volume":"31","author":"Suresh","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omton.2026.201262_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000974264.90665.ad","article-title":"PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA","volume":"7","author":"Han","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.omton.2026.201262_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113979","article-title":"Venetoclax plus cytarabine and azacitidine in relapsed\/refractory AML: An open-label, single-arm, phase 2 study","volume":"202","author":"You","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201262_bib28","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1093\/emboj\/cdf548","article-title":"Control of CBP co-activating activity by arginine methylation","volume":"21","author":"Chevillard-Briet","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2026.201262_bib29","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1126\/science.1065961","article-title":"A transcriptional switch mediated by cofactor methylation","volume":"294","author":"Xu","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201262_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15571","article-title":"Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition","volume":"8","author":"Shishkova","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201262_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217269","article-title":"Histone acetyltransferases as promising therapeutic targets in glioblastoma resistance","volume":"604","author":"Pathikonda","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2026.201262_bib32","doi-asserted-by":"crossref","first-page":"14789","DOI":"10.1073\/pnas.232568499","article-title":"Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal","volume":"99","author":"Rebel","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201262_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2022.01.024","article-title":"A synthetic covalent ligand of the C\/EBPbeta transactivation domain inhibits acute myeloid leukemia cells","volume":"530","author":"Abdel Ghani","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2026.201262_bib34","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1021\/bi002631b","article-title":"Methylation of histone H3 by coactivator-associated arginine methyltransferase 1","volume":"40","author":"Schurter","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.omton.2026.201262_bib35","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/1389450119666180110093713","article-title":"The Role of DNA Repair Pathways in AML Chemosensitivity","volume":"19","author":"Pearsall","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.omton.2026.201262_bib36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1590\/S1415-47572010005000018","article-title":"Non-homologous DNA end joining in normal and cancer cells and its dependence on break structures","volume":"33","author":"Poplawski","year":"2010","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.omton.2026.201262_bib37","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/0008-5472.CAN-18-0273","article-title":"MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells","volume":"78","author":"Bayley","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201262_bib38","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.1158\/0008-5472.CAN-10-0944","article-title":"Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair","volume":"70","author":"Luoto","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201262_bib39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201262_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-4598-7-32","article-title":"DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein","volume":"7","author":"An","year":"2008","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201262_bib41","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.celrep.2018.10.003","article-title":"Brd4's Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1","volume":"25","author":"Wu","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201262_bib42","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/s41375-020-0908-8","article-title":"CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP\/EP300-mutated lymphomas","volume":"34","author":"Veazey","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201262_bib43","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2012.96","article-title":"Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib\/multi-targeted inhibitors and JAK inhibitors","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201262_bib44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41419-019-1964-8","article-title":"Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia","volume":"10","author":"Ganesan","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omton.2026.201262_bib45","doi-asserted-by":"crossref","first-page":"67639","DOI":"10.18632\/oncotarget.18797","article-title":"Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming","volume":"8","author":"Bhanot","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201262_bib46","article-title":"Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs","volume":"33","author":"Ni","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201262_bib47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41416-021-01441-7","article-title":"Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)","volume":"125","author":"Lapidot","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201262_bib48","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201262_bib49","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2015.46","article-title":"Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells","volume":"29","author":"Bhanot","year":"2015","journal-title":"Leukemia"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:40:04Z","timestamp":1790253604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001384"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201262","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201262"}}